By activating both GIP and GLP-1 receptors, it enhances insulin sensitivity, regulates glucose metabolism, and significantly reduces hunger signals
On average, clinical trials show that patients can lose 15-20% of their body weight during treatment
This is a collaborative partnership between you and a medical team with deep experience in obesity treatment and bariatric medicine
Repeated injections in one area can make the skin sore or inflamed
Glucophage highlights of prescribing information, Bristol-Myers Squibb Company (2018) Wegovy highlights of prescribing information, Novo Nordisk Inc
Whats important to note, though, is how theyre offering GLP-1s: Brand-name semaglutide (Wegovy) Ive noticed this pattern with digital health companies: open up a weight-loss membership program and offer a brand name GLP-1